Revista Multidisciplinar Do Nordeste Mineiro · Nov 3, 2026
Integrated (multimodal) diagnostic strategies involving epigenetic biomarkers for the early diagnosis of Alzheimer's disease: a scoping review protocol
By Alves DCT, Zander LRM, Alves FBT et al.
Early biological characterization of Alzheimer's disease is essential for interventions at early stages, although the identification of neuropathological changes in the preclinical phase is challenged by the high heterogeneity of biomarkers and the complexity of regulatory mechanisms. In this context, multimodal strategies that integrate epigenetic biomarkers with other diagnostic modalities have been investigated to increase diagnostic and predictive accuracy, making it necessary to systematize their approaches, biological matrices, and integration methods. The objective of this protocol is to guide the mapping of multimodal diagnostic strategies that integrate epigenetic biomarkers with other modalities for the early detection of Alzheimer's disease. This is a scoping review protocol conducted according to the contemporary framework of the Joanna Briggs Institute (JBI) and structured for subsequent reporting according to PRISMA-ScR. The research question was based on the PCC (Population, Concept, and Context) acronym. Primary studies will be included involving cognitively unimpaired adults (with or without increased risk or preclinical evidence), individuals with mild cognitive impairment, and people with Alzheimer's disease, primarily at an early stage, that combine DNA methylation or regulatory noncoding RNAs with at least one additional diagnostic modality of a different nature. The search strategy covers the PubMed, Embase, Scopus, and Web of Science databases, with supplementary searching of reference lists. Publications in Portuguese, English, or Spanish published between August 24, 2021 and August 24, 2026 will be considered. Study selection will be performed independently by two reviewers, while data extraction will be conducted collaboratively by the same reviewers, with support from generative artificial intelligence and management software. Disagreements will be resolved by consensus or a third reviewer. Data will be analyzed using simple descriptive statistics and narrative synthesis. The investigated applications and their evidence gaps are expected to be mapped, without intending to establish superiority among strategies or recommendations for clinical use.